Zeglu-GP1 Tablets – Glimepiride 1mg Metformin 500mg Pioglitazone 15mg Tablets Manufacturer, Supplier, Franchise In India
Zeglu-GP1 Tablets are a triple-combination oral antidiabetic medication containing Glimepiride 1 mg, Metformin 500 mg, and Pioglitazone 15 mg. This formulation is designed for the management of type 2 diabetes mellitus in patients whose blood sugar levels are not adequately controlled with diet, exercise, or single/dual therapy. By targeting multiple pathways involved in glucose regulation, Zeglu-GP1 offers comprehensive glycemic control.
Glimepiride stimulates insulin secretion from the pancreas to lower blood sugar levels. Metformin enhances insulin sensitivity, reduces glucose production in the liver, and decreases intestinal glucose absorption. Pioglitazone further improves insulin sensitivity in peripheral tissues, helping the body utilize glucose more effectively. Together, these three agents provide balanced and sustained blood sugar management.
Key Benefits & Uses of Zeglu-GP1 Tablets
Zeglu-GP1 Tablets help control both fasting and post-prandial blood glucose levels, ensuring effective long-term management of type 2 diabetes. The triple-action mechanism addresses insulin deficiency, insulin resistance, and hepatic glucose production, leading to better overall glycemic stability.
Regular use may help reduce the risk of diabetes-related complications, including cardiovascular disease, kidney damage, and nerve disorders. The combination of three proven antidiabetic agents in a single tablet improves convenience, adherence, and treatment effectiveness when taken alongside a healthy diet and lifestyle.
